Why the study?
Does intravenous magnesium infusion and sotalol withdrawal treat sotalol-induced torsade de pointes in a patient with atrial fibrillation?
Does intravenous magnesium infusion and sotalol withdrawal treat sotalol-induced torsade de pointes in a patient with atrial fibrillation?
Intravenous magnesium infusion and sotalol withdrawal successfully managed sotalol-induced torsade de pointes, highlighting the risk of late pro-arrhythmic effects due to bradycardia upon reversion to sinus rhythm.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to late sotalol proarrhythmia risk in AF; single case leaves open generalizability of magnesium-based management.
A 69 year old woman was treated with sotalol (320 mg daily) for intermittent atrial fibrillation. Sotalol was initially well tolerated and reversion to sinus rhythm with sinus bradycardia occurred 4 weeks after initiation of therapy. Shortly thereafter, the patient developed recurrent syncope due to torsade de pointes. This was treated successfully with intravenous magnesium infusion and withdrawal of sotalol. Subsequently, the atrial fibrillation was adequately managed using amiodarone, with no recurrence of torsade de pointes. Development of bradycardia associated with reversion to sinus rhythm represents a potential cause of 'late' pro-arrhythmic effects of sotalol.
No takes yet. Share an insight, caveat, or question.
Arstall et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: